Helena Horton:: A year after starting treatment with daraxonrasib, 76.6% of pancreatic cancer patients were alive; usually 40-45% of patients given chemotherapy alone survive a year.Pancreatic cancer undetectable for one in 12 patients in trial. Hailed as ‘biggest breakthrough in decades ¦ The Guardian
Discovered: Nov 21, 2026 15:49 (UTC) Helena Horton:: A year after starting treatment with daraxonrasib, 76.6% of pancreatic cancer patients were alive; usually 40-45% of patients given chemotherapy alone survive a year.Pancreatic cancer undetectable for one in 12 patients in trial. Hailed as ‘biggest breakthrough in decades ¦ The Guardian <– Go Science go!
With the previously announced trail of the mRNA vaccine against KRAS and a custom mRNA vaccine, more and more progress against pancreatic cancer, yes!
Previously
- April 19, 2026: ME:: tl;dr-ing if your pancreatic cancer is operable, a custom mRNA vaccine using the tumor cells removed during your operation appears to work in a small 16 person trial AND there is also an off-the-shelf vaccine that targets a protein called KRAS ; Kaitlin Sullivan, Marina Kopf, Anne Thompson:: Pancreatic cancer mRNA vaccine shows lasting results in an early trial
- August 1, 2020: Please consider donating to my team, Sofia’s Camera Club, for the virtual Cypress Challenge in honour of my mother who died of Pancreatic Cancer in 2013. 100% of your donations go to pancreatic cancer; this is a zero overhead ride
QUOTE
- Read the whole thing: Pill to treat pancreatic cancer hailed as ‘biggest breakthrough in decades’ ¦ Pancreas cancer ¦ The Guardian
In one in 12 of the patients given the drug, daraxonrasib, during a trial, the cancer became undetectable, and the tumours stopped growing in almost all of the 61 patients. The trial participants had recently been diagnosed with advanced pancreatic cancer that had spread to other parts of the body.
Though doctors have said the pill cannot yet be considered a cure, and they do not know how long it can keep the disease at bay, they have said it is encouraging news because it appears it will offer patients more time, even if it does not cause full remission.